Shorter Duration of Blinatumomab Administration to 14 Days Has Same Efficacy and Safety Profile in Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Single‐Center Study
A 14-day blinatumomab administration may be a promising and well-tolerated regimen in r/r BCP-ALL, offering the same ORR and survival rates.
Authors
- Jinyu Kong
- Baoquan Song (ORCID: https://orcid.org/0000-0002-6046-8209)
- Wenjing Miao
- Yin Liu (ORCID: https://orcid.org/0000-0001-6014-061X)
- Huiying Qiu (ORCID: https://orcid.org/0000-0001-5211-725X)
- Jialing Lu (ORCID: https://orcid.org/0009-0001-8757-6154)
- Xin Kong
Institutions
- Nanchang University (CN)
- Soochow University (CN)
- Shanghai Traditional Chinese Medicine Hospital (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Acta Haematologica
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1159/000542060
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00